140 related articles for article (PubMed ID: 10386485)
21. Zafirlukast improves asthma symptoms and quality of life in patients with moderate reversible airflow obstruction.
Nathan RA; Bernstein JA; Bielory L; Bonuccelli CM; Calhoun WJ; Galant SP; Hanby LA; Kemp JP; Kylstra JW; Nayak AS; O'Connor JP; Schwartz HJ; Southern DL; Spector SL; Williams PV
J Allergy Clin Immunol; 1998 Dec; 102(6 Pt 1):935-42. PubMed ID: 9847434
[TBL] [Abstract][Full Text] [Related]
22. Leukotriene E(4)-induced persistent eosinophilia and airway obstruction are reversed by zafirlukast in patients with asthma.
Laitinen A; Lindqvist A; Halme M; Altraja A; Laitinen LA
J Allergy Clin Immunol; 2005 Feb; 115(2):259-65. PubMed ID: 15696079
[TBL] [Abstract][Full Text] [Related]
23. Leukotriene-receptor antagonists.
Lipworth BJ
Lancet; 1999 Jan; 353(9146):57-62. PubMed ID: 10023966
[TBL] [Abstract][Full Text] [Related]
24. [Measurement of cytokines in patients with exercise-induced asthma treated with anti-leukotrienes].
Flores Sandoval G; Orea Solano M; Cortés Padilla V; Santos Argumedo L
Rev Alerg Mex; 2002; 49(5):143-8. PubMed ID: 12501759
[TBL] [Abstract][Full Text] [Related]
25. Two first-line therapies in the treatment of mild asthma: use of peak flow variability as a predictor of effectiveness.
Nathan RA; Minkwitz MC; Bonuccelli CM
Ann Allergy Asthma Immunol; 1999 May; 82(5):497-503. PubMed ID: 10353583
[TBL] [Abstract][Full Text] [Related]
26. Effectiveness and tolerability of zafirlukast for the treatment of asthma in children.
Pearlman DS; Lampl KL; Dowling PJ; Miller CJ; Bonuccelli CM
Clin Ther; 2000 Jun; 22(6):732-47. PubMed ID: 10929920
[TBL] [Abstract][Full Text] [Related]
27. Zafirlukast treatment for acute asthma: evaluation in a randomized, double-blind, multicenter trial.
Silverman RA; Nowak RM; Korenblat PE; Skobeloff E; Chen Y; Bonuccelli CM; Miller CJ; Simonson SG
Chest; 2004 Nov; 126(5):1480-9. PubMed ID: 15539716
[TBL] [Abstract][Full Text] [Related]
28. Pulmonary infiltrates, eosinophilia, and cardiomyopathy following corticosteroid withdrawal in patients with asthma receiving zafirlukast.
Wechsler ME; Garpestad E; Flier SR; Kocher O; Weiland DA; Polito AJ; Klinek MM; Bigby TD; Wong GA; Helmers RA; Drazen JM
JAMA; 1998 Feb; 279(6):455-7. PubMed ID: 9466639
[TBL] [Abstract][Full Text] [Related]
29. [Influence of zafirlukast on pulmonary functions and quality of life in patients with asthma].
Xiang XD; Zhou R; Chen Y
Hunan Yi Ke Da Xue Xue Bao; 2001 Jun; 26(3):251-3. PubMed ID: 12536697
[TBL] [Abstract][Full Text] [Related]
30. Enhanced prostaglandin E2 secretion in sputum from asthmatic patients after zafirlukast therapy.
Tsai JJ; Su YC; Chan SC; Ho CK; Feng TC
J Formos Med Assoc; 2001 Apr; 100(4):241-3. PubMed ID: 11393122
[TBL] [Abstract][Full Text] [Related]
31. [Therapeutic effects of an antileukotriene in children with moderate-severe persistent asthma].
Cuevas Hernández MM; Arias Hernández RM
Rev Alerg Mex; 2004; 51(6):206-9. PubMed ID: 15794412
[TBL] [Abstract][Full Text] [Related]
32. A drug interaction between zafirlukast and theophylline.
Katial RK; Stelzle RC; Bonner MW; Marino M; Cantilena LR; Smith LJ
Arch Intern Med; 1998 Aug 10-24; 158(15):1713-5. PubMed ID: 9701106
[TBL] [Abstract][Full Text] [Related]
33. [Zafirlukast therapy of patients with mild-to-moderate bronchial asthma].
Naményi M; Puha K; Pánczél G; Mikó P; Fäller K; Dér K
Orv Hetil; 1999 Jun; 140(24):1353-6. PubMed ID: 10439636
[TBL] [Abstract][Full Text] [Related]
34. Antitussive effect of the leukotriene receptor antagonist zafirlukast in subjects with cough-variant asthma.
Dicpinigaitis PV; Dobkin JB; Reichel J
J Asthma; 2002 Jun; 39(4):291-7. PubMed ID: 12095178
[TBL] [Abstract][Full Text] [Related]
35. The effects of add-on zafirlukast treatment to budesonide on bronchial hyperresponsiveness and serum levels of eosinophilic cationic protein and total antioxidant capacity in asthmatic patients.
Cakmak G; Demir T; Gemicioglu B; Aydemir A; Serdaroglu E; Donma O
Tohoku J Exp Med; 2004 Dec; 204(4):249-56. PubMed ID: 15572850
[TBL] [Abstract][Full Text] [Related]
36. A single dose of zafirlukast reduces LTD4-induced bronchoconstriction in patients on maintenance inhaled corticosteroid therapy.
Smith LJ; Hanby LA; Lavins BJ; Simonson SG
Ann Allergy Asthma Immunol; 1998 Jul; 81(1):43-9. PubMed ID: 9690572
[TBL] [Abstract][Full Text] [Related]
37. Safety of zafirlukast: results of a postmarketing surveillance study on 7976 patients in England.
Twaites BR; Wilton LV; Shakir SA
Drug Saf; 2007; 30(5):419-29. PubMed ID: 17472420
[TBL] [Abstract][Full Text] [Related]
38. Zafirlukast for asthma.
Med Lett Drugs Ther; 1996 Dec; 38(990):111-2. PubMed ID: 8988153
[No Abstract] [Full Text] [Related]
39. Drug-induced lupus in a child after treatment with zafirlukast (Accolate).
Finkel TH; Hunter DJ; Paisley JE; Finkel RS; Larsen GL
J Allergy Clin Immunol; 1999 Mar; 103(3 Pt 1):533-4. PubMed ID: 10069891
[No Abstract] [Full Text] [Related]
40. Safety of leukotriene receptor antagonists in pregnancy.
Bakhireva LN; Jones KL; Schatz M; Klonoff-Cohen HS; Johnson D; Slymen DJ; Chambers CD;
J Allergy Clin Immunol; 2007 Mar; 119(3):618-25. PubMed ID: 17336611
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
